The incidence of esophageal adenocarcinomas (EAC) has increased at an alarming rate (>400%) in the last few decades far exceeding any other cancer type in the United States, while the prognosis has remained poor (1). Most EACs are initiated by replacement of normal squamous epithelium with metaplastic mucosa known as Barrett's esophagus (BE), which subsequently progress through a dysplastic stage into invasive carcinomas (2). Although BE-affected individuals carry a 30-125 fold greater risk of developing EAC when compared to an age-matched population (3), the estimated rate of cancer progression among BE individuals is only 1 per 200 patient-years (2). This makes it difficult to identify BE patients who are at an increased risk for cancer development, and is one of the major clinical challenges in this disease. Endoscopy-based surveillance in BE patients has shown only a minimal impact in reducing cancer mortality, and is certainly not cost-effective (2). Though histology based evaluation for high-grade dysplasia (HGD) is currently used for assessing cancer risk in patients with BE, the approach is not optimal owing both to the marked inter-observer variability in interpreting dysplasia (4), and to the highly variable rates of progression to EAC (16-50% over 7 years) among HGD cases (2). Therefore, identification of novel biomarkers that reliably aid in risk stratification in BE would allow for the development of more rational surveillance strategies aimed at early cancer detection, in addition to providing a novel class of therapeutic targets for this deadly disease. Moreover, it will additionally help in curtailing health care costs by refining current screening and surveillance programs. Accordingly, the primary objective of this proposal is to identify RNA-based biomarkers associated with the risk of malignant progression in BE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Case Western Reserve University
United States
Zip Code
Sanchis-Gomar, Fabian; Lucia, Alejandro; Yvert, Thomas et al. (2015) Physical inactivity and low fitness deserve more attention to alter cancer risk and prognosis. Cancer Prev Res (Phila) 8:105-10
Abrams, Julian A; Appelman, Henry D; Beer, David G et al. (2014) Barrett's Esophagus Translational Research Network (BETRNet): the pivotal role of multi-institutional collaboration in esophageal adenocarcinoma research. Gastroenterology 146:1586-90
Kaz, Andrew M; Grady, William M (2014) Epigenetic biomarkers in esophageal cancer. Cancer Lett 342:193-9
Alashkar, Bronia; Faulx, Ashley L; Hepner, Ashley et al. (2014) Development of a program to train physician extenders to perform transnasal esophagoscopy and screen for Barrett's esophagus. Clin Gastroenterol Hepatol 12:785-92
Berger, Nathan A (2014) Obesity and cancer pathogenesis. Ann N Y Acad Sci 1311:57-76
Chak, Amitabh; Alashkar, Bronia M; Isenberg, Gerard A et al. (2014) Comparative acceptability of transnasal esophagoscopy and esophageal capsule esophagoscopy: a randomized, controlled trial in veterans. Gastrointest Endosc 80:774-82
Wolf, W Asher; Dellon, Evan S; Shaheen, Nicholas J (2014) Esophageal diseases. Gastrointest Endosc 80:374-9
Garman, Katherine S; Owzar, Kouros; Hauser, Elizabeth R et al. (2013) MicroRNA expression differentiates squamous epithelium from Barrett's esophagus and esophageal cancer. Dig Dis Sci 58:3178-88
Greer, K B; Kresak, A; Bednarchik, B et al. (2013) Insulin/Insulin-Like Growth Factor-1 Pathway in Barrett's Carcinogenesis. Clin Transl Gastroenterol 4:e31
Orman, Eric S; Li, Nan; Shaheen, Nicholas J (2013) Efficacy and durability of radiofrequency ablation for Barrett's Esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:1245-55

Showing the most recent 10 out of 15 publications